<DOC>
	<DOCNO>NCT01177371</DOCNO>
	<brief_summary>RATIONALE : Giving high dos chemotherapy drug , busulfan cyclophosphamide , donor bone marrow transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine , methylprednisolone , methotrexate transplant may stop happen . PURPOSE : This clinical trial study high-dose busulfan high-dose cyclophosphamide follow donor bone marrow transplant treat patient leukemia , myelodysplastic syndrome , multiple myeloma , recurrent Hodgkin Non-Hodgkin lymphoma .</brief_summary>
	<brief_title>High-Dose Busulfan High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant Treating Patients With Leukemia , Myelodysplastic Syndrome , Multiple Myeloma , Recurrent Hodgkin Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . To determine toxicity efficacy high-dose chemotherapy regimen employ busulfan , cyclophosphamide , allogeneic bone marrow transplantation . II . To ascertain feasibility ( safety ) efficacy use intensive chemotherapy regimen ( busulfan cyclophosphamide ) follow allogeneic bone marrow transplantation patient leukemia , myelodysplastic syndrome , multiple myeloma , lymphoma . OUTLINE : HIGH-DOSE CHEMOTHERAPY : Patients receive oral busulfan every 6 hour day -8 -5 cyclophosphamide IV 2 hour day -4 -3 , -4 -2 . TRANSPLANTATION : Patients undergo allogeneic bone marrow transplant IV 2-3 hour day 0 . GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS : Patients receive cyclosporine IV 6 hour day -1 , 10 hour twice daily day 0-20 , orally every 12 hour begin day 21 continue 12 month taper 9 month . Patients also receive methylprednisolone IV orally begin day 8 continue 7 month taper 4 month . Some patient may also receive methotrexate IV day 1 , 3 6 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Criteria Acute nonlymphocytic leukemia ( FAB type M1M7 ) first , second remission , early first second bone marrow relapse ( &gt; 31 % marrow blast circulate peripheral blast ) All patient acute promyelocytic leukemia first complete remission receive retinoic acid chemotherapy eligible Acute lymphocytic leukemia first second remission , early first second bone marrow relapse ( 31 % marrow blast circulate peripheral blast ) Pediatric ALL patient first complete remission eligible Chronic myelogenous leukemia first second chronic phase , accelerate phase Myelodysplastic syndrome = &lt; 50 year Lymphoma patient age = &lt; 50 year ( non Hodgkins Hodgkins ) first second relapse , refractory disease , ineligible autologous bone marrow transplantation tumor bone marrow Multiple myeloma patient age = &lt; 50 relapsed refractory least 2 chemoradiation chemotherapy regimens Patients fail previous allogeneic bone marrow transplant Patients inborn error metabolism ECOG performance status 0 1 Karnofsky performance status &gt; = 70 % Patients must HTLVIII ( HIV ) antibody negative Acute chronic leukemia patient must age = &lt; 50 year ; patient age 60 year diseases syngeneic donor eligible Patients ( bone marrow donor ) HTLVIII ( HIV ) antibody positive ineligible study Patients must active infection Patients must cytotoxic chemotherapeutic agent least 4 week transplant condition regimen begin It recommend require acute leukemia patient undergo transplantation first remission must receive least one course consolidation therapy Patients undergo transplant early relapse eligible transplant first second relapse Patients must history acute myocardial infarction 6 month prior transplantation , angina pectoris require nitrate therapy , uncontrolled major ventricular dysrhythmia , uncontrolled hypertension , uncontrolled congestive heart failure A gatedpool radionuclide scan fraction must &gt; = 50 % Serum creatinine must = &lt; 1.8 % 24 hour creatinine clearance must &gt; = 60ml/min Serum direct bilirubin &gt; = 1.8mg % , serum SGOT SGPT &gt; twice normal exclude patient study Severe symptomatic CNS disease etiology CNS leukemia exclude patient study FEV1 DLco ( correct ) must &gt; = 60 % normal pO2 &gt; 60mmHg Insulindependent diabetes mellitus uncompensated major thyroid adrenal dysfunction render patient ineligible Written inform consent must obtain Patients treat previously radiation therapy excess 1000 cGy ( rad ) thoracic abdominal port , excess 3000 cGy ( rad ) cranialspinal port , eligible protocol eligible study DONOR : All genotypically HLA D/DR identical sibling eligible bone marrow donor long general medical condition permit safe use general spinal anesthesia ; select donor HLAidentical may consider use long D/DR identical , MLC compatible , good condition safely undergo spinal general anesthesia DONOR : This protocol allow use donor unrelated HLAA , b , C , D/Dr identical MLC ( mixed lymphocyte culture ) compatible Patient must adequate insurance cover cost transplant hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>